- Home
- MFIN vs SLS Comparison
MFIN vs SLS Comparison
Compare MFIN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- SLS
- Stock Information
- Founded
- MFIN 1995
- SLS 2012
- Country
- MFIN United States
- SLS United States
- Employees
- MFIN N/A
- SLS N/A
- Industry
- MFIN Finance: Consumer Services
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- SLS Health Care
- Exchange
- MFIN Nasdaq
- SLS Nasdaq
- Market Cap
- MFIN 223.8M
- SLS 185.3M
- IPO Year
- MFIN 1996
- SLS N/A
- Fundamental
- Price
- MFIN $10.71
- SLS $1.91
- Analyst Decision
- MFIN Strong Buy
- SLS Strong Buy
- Analyst Count
- MFIN 1
- SLS 1
- Target Price
- MFIN $12.00
- SLS $7.00
- AVG Volume (30 Days)
- MFIN 42.9K
- SLS 1.9M
- Earning Date
- MFIN 10-28-2025
- SLS 08-12-2025
- Dividend Yield
- MFIN 4.48%
- SLS N/A
- EPS Growth
- MFIN N/A
- SLS N/A
- EPS
- MFIN 1.75
- SLS N/A
- Revenue
- MFIN $332,256,000.00
- SLS N/A
- Revenue This Year
- MFIN N/A
- SLS N/A
- Revenue Next Year
- MFIN $1.53
- SLS N/A
- P/E Ratio
- MFIN $6.12
- SLS N/A
- Revenue Growth
- MFIN 16.48
- SLS N/A
- 52 Week Low
- MFIN $7.40
- SLS $0.77
- 52 Week High
- MFIN $10.98
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- MFIN 60.53
- SLS 57.67
- Support Level
- MFIN $10.27
- SLS $1.75
- Resistance Level
- MFIN $10.73
- SLS $2.01
- Average True Range (ATR)
- MFIN 0.27
- SLS 0.13
- MACD
- MFIN 0.00
- SLS 0.01
- Stochastic Oscillator
- MFIN 80.95
- SLS 75.00
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.